

CORRECTION

Open Access



Correction to: Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study

William R. Lumry^{1*}, Bruce Zuraw², Marco Cicardi³, Timothy Craig⁴, John Anderson⁵, Aleena Banerji⁶, Jonathan A. Bernstein⁷, Teresa Caballero⁸, Henriette Farkas⁹, Richard G. Gower¹⁰, Paul K. Keith¹¹, Donald S. Levy¹², H. Henry Li¹³, Markus Magerl¹⁴, Michael Manning¹⁵, Marc A. Riedl¹⁶, John-Philip Lawo¹⁷, Subhansu Prusty¹⁷, Thomas Machnig¹⁷ and Hilary Longhurst^{18,19} on behalf of the COMPACT Investigators

Correction to: *Orphanet J Rare Dis* (2021) 16:86

<https://doi.org/10.1186/s13023-020-01658-4>

Following the publication of the original article [1] the authors informed us of an error in the second paragraph under ‘Study population’ of the ‘Results’ section.

The paragraph should read:

“Half of the patients in the study (n = 64, 50.8%) were participants in the double-blind COMPACT study, thus were using C1-INH(SC) prophylaxis prior to continuing into the open-label study (Table 1). An additional 15 patients (11.9%) were using other forms of HAE prophylaxis (intravenous C1-INH [C1-INH[IV]] or oral danazol) within the 3-month period prior to the open-label study”.

The original article has already been updated as above.

Author details

¹AARA Research Center, 10100 N. Central Expressway, Suite 100, Dallas, TX 75231, USA. ²Department of Medicine, UC San Diego, La Jolla, CA, USA. ³University of Milan, Milan, Italy. ⁴Penn State University College of Medicine, Hershey, PA, USA. ⁵Clinical Research Center of Alabama, Birmingham, AL, USA. ⁶Massachusetts General Hospital, Boston, MA, USA. ⁷University of Cincinnati College of Medicine and Bernstein Clinical Research Center, LLC, Cincinnati, OH, USA. ⁸Allergy Department, Hospital La Paz Institute for Health Research (IdiPaz), Biomedical Research Network On Rare Diseases (CIBERER U754), Madrid, Spain. ⁹Hungarian Angioedema Reference Center, 3Rd Department of Internal Medicine, Semmelweis University, Budapest, Hungary. ¹⁰Mary-clif Clinical Research, Spokane, WA, USA. ¹¹McMaster University, Hamilton, ON, USA. ¹²UC Irvine, Orange, CA, USA. ¹³Institute for Asthma and Allergy, Chevy Chase, MD, USA. ¹⁴Department of Dermatology and Allergy, Charité, Universitätsmedizin Berlin, Berlin, Germany. ¹⁵Medical Research of Arizona, Scottsdale, AZ, USA. ¹⁶Division of Rheumatology, Allergy and Immunology, University of California, San Diego, La Jolla, CA, USA. ¹⁷CSL Behring GmbH, Emil-von-Behring-Strasse 76, Marburg, Germany. ¹⁸University College Hospital, London, UK. ¹⁹Auckland District Health Board, Auckland, New Zealand.

Published online: 28 July 2021

The original article can be found online at <https://doi.org/10.1186/s13023-020-01658-4>.

*Correspondence: Lumrymd@AARAResearch.com

¹ AARA Research Center, 10100 N. Central Expressway, Suite 100, Dallas, TX 75231, USA

Full list of author information is available at the end of the article



© The Author(s) 2021. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reference

1. Lumry, et al. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study. *Orphanet J Rare Dis.* 2021;16:86. <https://doi.org/10.1186/s13023-020-01658-4>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.